Hattie Hayes

The diagnostic imaging experts will provide education through the Cybersight platform

In a conversation at ESCRS, the CEO said by 2028, Aurion Biotech hopes to see global registration for its corneal endothelial disease therapies.

Novartis acquired Gyroscope Holdings Limited from Syncona in February 2022

At this year's ESCRS meeting, we visited the Oertli Instruments booth, where co-CEO and co-owner Thomas Bosshard highlighted the company's 3-platform approach.

At the 2023 European Society Of Cataract & Refractive Surgeons (ESCRS) meeting in Vienna, Krysten Williams, head of marketing and education at Heidelberg Engineering, spoke to our team about the newest imaging advancements in the clinic and the operating room.

Jorge Alio, MD, PhD, FEBOpthhal spoke with our team about his Binkhorst Medal lecture topic, the future of cataract and refractive surgery, while at the 2023 ESCRS meeting in Vienna, Austria.

Euan Thomson, the President of Ophthalmic Devices, Carl Zeiss Meditec spoke with our team about integrated workflow solutions and how they can benefit cataract procedures while at the 2023 ESCRS meeting in Vienna, Austria.

The non-profit will partner with the imaging company to prevent blindness and fund new retinoblastoma research.

The company announced new data on outcomes for both open and narrow angle glaucoma patients.

Advancements from Carl Zeiss Medical AG in the cataract and cornea space include a new intraocular lens and therapeutic laser enhancements.

The EUREQUO Annual Report celebrates 15 years and over 4 million surgical procedures in the registry.

VG901 is a gene therapy for CNGA1-associated RP.

The geographic atrophy treatment was approved by the FDA in the US earlier this month.

The study met its primary efficacy endpoint for the neovascular age-related macular degeneration (nAMD) treatment.

IZERVAY is expected to be available in the United States within 2 to 4 weeks.

This year’s meeting will include boxing rings, ball gowns and a full schedule of engaging new symposia

The Biocon Biologics, Ltd product moves on to review by the European Commission, with an expected decision in late September 2023.

The London-based company will use regenerative medicine to fight ocular disease.

The open-access tool is the official registry partner of the European Glaucoma Society.

The company seeks to replicate European success of the ELIOS procedure in the US market.

The pharmaceutical company will present study results at the World Glaucoma Congress.

The live streamed event will cover topics including DME, CME, AON and more.

The two winners were awarded a €60,000 prize for their work to treat degenerative retinal disease.

Researchers totaled the societal and healthcare costs of inherited retinal diseases.

The lenses are designed to correct and prevent myopia in children ages 6 to 14.

Did you miss the 2023 European Society of Ophthalmology congress? Don't worry – you can catch up with our video coverage.

Ophthalmology Times Europe© is proud to cover the European Society of Ophthalmology 2023. We spoke to SOE presenter Panayiota Founti, PhD, FEBO, Consultant Ophthalmic Surgeon & Training Director, Glaucoma Service Moorfields Eye Hospital, London, UK.

The new company debuted with £96 million in funding to target retinal diseases.

The EACCME accreditation is renewed through 2025.